These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8956785)

  • 1. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Br J Cancer; 1996 Dec; 74(11):1730-3. PubMed ID: 8956785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
    Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Adv Exp Med Biol; 1999; 457():567-70. PubMed ID: 10500835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ; Illand M; Kim YT; Paul J; Brown R
    Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
    Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
    Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
    Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
    Dempke WC; Shellard SA; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1991 Mar; 12(3):525-8. PubMed ID: 1901253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro testing of platinum-based drugs on a panel of human ovarian tumour cell lines.
    Garner CM; Hubbold LM; Chakraborti PR
    Br J Biomed Sci; 2002; 59(1):15-9. PubMed ID: 12000179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
    Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
    Hernlund E; Hjerpe E; Avall-Lundqvist E; Shoshan M
    Mol Cancer Ther; 2009 Jul; 8(7):1916-23. PubMed ID: 19567816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.